Basic Information
| LncRNA/CircRNA Name | AFAP1-AS1 |
| Synonyms | NA |
| Region | GRCh38_4:7754090-7778928 |
| Ensemble | ENSG00000272620 |
| Refseq | NR_026892 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, in vitro knockdown, etc. |
| Sample | TNBC tissues, normal mammary epithelial cell lines (184A1 and MCF-10A) and human breast cancer cell lines (BT474, MCF-7, T47D, BT483, BT20, MDA-MB-468, BT549, and MDA-MB-231) |
| Expression Pattern | up-regulated |
| Function Description | AFAP1-AS1 was overexpressed in TNBC tissues and cells. Overexpression of LncRNA AFAP1-AS1 was associated with poor prognosis in TNBC patients. Moreover, we demonstrated that upregulation of AFAP1-AS1 promoted cell proliferation and invasion, and inhibited cell apoptosis in vitro, while overexpression of AFAP1-AS1 promoted tumor growth in vivo. Our results also revealed that upregulation of AFAP1-AS1 activated Wnt/?-catenin pathway to promote tumorigenesis and cell invasion by increasing the expression of C-myc and epithelial-mesenchymal transition-related molecules in TNBC. |
| Pubmed ID | 30505272 |
| Year | 2018 |
| Title | AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/?-Catenin Signaling Pathway in Triple-Negative Breast Cancer. |
External Links
| Links for AFAP1-AS1 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |